Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR

Aminopeptidase inhibitors are receiving attention as combination chemotherapeutic agents for the treatment of refractory acute myeloid leukemia. However, the factors determining therapeutic efficacy remain elusive. Here we identified the molecular basis of acquired resistance to CHR2863, an orally a...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Verbrugge, Sue Ellen, Al, Marjon, Assaraf, Yehuda G., Kammerer, Sarah, Chandrupatla, Durga M.S.H., Honeywell, Richard, Musters, Rene P.J., Giovannetti, Elisa, O'Toole, Tom, Scheffer, George L., Krige, David, de Gruijl, Tanja D., Niessen, Hans W.M., Lems, Willem F., Kramer, Pieternella A., Scheper, Rik J., Cloos, Jacqueline, Ossenkoppele, Gert J., Peters, Godefridus J., Jansen, Gerrit
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2015
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4868683/
https://ncbi.nlm.nih.gov/pubmed/26496029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6169
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items